Fig. 9

Potential of the IRscore in predicting ICB response and potential compounds and druggable targets. A The abundance of immune and stromal cell types across low to high IRscore ccRCC samples in TCGA-KIRC dataset. B Associations of the IRscore with the activity of steps within the cancer-immunity cycle in TCGA-KIRC dataset. C Associations of the IRscore with the enrichment score of known biological processes in TCGA-KIRC dataset. D Distribution of the IRscore across different responses to anti-PD-L1 therapy in the IMvigor210 dataset. E Percentage of different therapeutic responses in low and high IRscore groups. F K-M curves of OS between groups. G, H Correlations between the IRscore and the AUC values of CTRP- or PRISM-derived compounds (left), and differences in the AUC values between low and high IRscore groups. *** p < 0.001. I, J Relationships of the IRscore with the protein expression and CERES score of druggable targets. Blue, positive correlation; red, negative correlation